{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:56:35Z","timestamp":1772027795072,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,1,25]],"date-time":"2017-01-25T00:00:00Z","timestamp":1485302400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s10147-017-1091-4","type":"journal-article","created":{"date-parts":[[2017,1,24]],"date-time":"2017-01-24T23:30:29Z","timestamp":1485300629000},"page":"593-599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidence of and risk factors associated with nedaplatin-related hypersensitivity reactions"],"prefix":"10.1007","volume":"22","author":[{"given":"Yuki","family":"Kawarada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayaka","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Risa","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetaka","family":"Iwamizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Kumakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyofumi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,25]]},"reference":[{"key":"1091_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/207084","author":"N Makrilia","year":"2010","unstructured":"Makrilia N, Syrigou E, Kaklamanos I et al (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. doi: 10.1155\/2010\/207084","journal-title":"Met Based Drugs"},{"key":"1091_CR2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1006\/gyno.2001.6513","volume":"84","author":"M Markman","year":"2002","unstructured":"Markman M (2002) Hypersensitivity reactions to carboplatin. Gynecol Oncol 84:353\u2013354","journal-title":"Gynecol Oncol"},{"key":"1091_CR3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ygyno.2006.04.002","volume":"103","author":"M Navo","year":"2006","unstructured":"Navo M, Kunthur A, Badell ML et al (2006) Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 103:608\u2013613","journal-title":"Gynecol Oncol"},{"key":"1091_CR4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2006.10.047","volume":"105","author":"JR Schwartz","year":"2007","unstructured":"Schwartz JR, Bandera C, Bradley A et al (2007) Does the platinum-free interval predict the incidence or severity of hypersensitivity reactions to carboplatin? The experience from Women and Infants\u2019 Hospital. Gynecol Oncol 105:81\u201383","journal-title":"Gynecol Oncol"},{"key":"1091_CR5","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.clinthera.2015.03.012","volume":"37","author":"T Okayama","year":"2015","unstructured":"Okayama T, Ishikawa T, Sugatani K et al (2015) Hypersensitivity reactions to oxaliplatin: identifying the risk factors and judging the efficacy of a desensitization protocol. Clin Ther 37:1259\u20131269","journal-title":"Clin Ther"},{"key":"1091_CR6","doi-asserted-by":"crossref","first-page":"10516","DOI":"10.1038\/srep10516","volume":"5","author":"Y Liu","year":"2015","unstructured":"Liu Y, Yu S, Liu S et al (2015) Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: a meta-analysis. Sci Rep 5:10516","journal-title":"Sci Rep"},{"key":"1091_CR7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3892\/mco.2015.504","volume":"3","author":"J Shan","year":"2015","unstructured":"Shan J, Xiong Y, Wang D et al (2015) Nedaplatin- versus cisplatin-based chemotherapy in the survival time of patients with non-small cell lung cancer. Mol Clin Oncol 3:543\u2013549","journal-title":"Mol Clin Oncol"},{"key":"1091_CR8","first-page":"1551","volume":"19","author":"Y Yokoyama","year":"2008","unstructured":"Yokoyama Y, Takano T, Nakahara K et al (2008) A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma. Tohoku Gynecologic Cancer Unit Study. Oncol Rep 19:1551\u20131556","journal-title":"Oncol Rep"},{"key":"1091_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3892\/or.2012.1814","volume":"28","author":"S Yamaguchi","year":"2012","unstructured":"Yamaguchi S, Nishimura R, Yaegashi N et al (2012) Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma. Japanese Gynecologic Oncology Group study (JGOG1065). Oncol Rep 28:487\u2013493","journal-title":"Oncol Rep"},{"key":"1091_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ygyno.2012.05.010","volume":"126","author":"M Takekuma","year":"2012","unstructured":"Takekuma M, Hirashima Y, Ito K et al (2012) Phase II trial of paclitaxel and nedaplatin in patients with advanced\/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study. Gynecol Oncol 126:341\u2013345","journal-title":"Gynecol Oncol"},{"key":"1091_CR11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00280-009-1056-z","volume":"65","author":"H Kurita","year":"2010","unstructured":"Kurita H, Yamamoto E, Nozaki S et al (2010) Multicenter phase 2 study of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Cancer Chemother Pharmacol 65:503\u2013508","journal-title":"Cancer Chemother Pharmacol"},{"key":"1091_CR12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/jjco\/hyq196","volume":"41","author":"T Ohashi","year":"2011","unstructured":"Ohashi T, Ohnishi M, Tanahashi S et al (2011) Efficacy and toxicity of concurrent chemoradiotherapy with nedaplatin and S-1 for head and neck cancer. Jpn J Clin Oncol 41:348\u2013352","journal-title":"Jpn J Clin Oncol"},{"key":"1091_CR13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/00016489.2014.952046","volume":"135","author":"H Hoshikawa","year":"2015","unstructured":"Hoshikawa H, Kishino T, Mori T et al (2015) Clinical outcomes of nedaplatin and S-1 treatment with concurrent radiotherapy in advanced head and neck cancer. Acta Otolaryngol 135:103\u2013108","journal-title":"Acta Otolaryngol"},{"key":"1091_CR14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(15)00305-8","volume":"16","author":"T Shukuya","year":"2015","unstructured":"Shukuya T, Yamanaka T, Seto T et al (2015) Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. Lancet Oncol 16:1630\u20131638","journal-title":"Lancet Oncol"},{"key":"1091_CR15","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1111\/cas.12538","volume":"105","author":"T Iwamoto","year":"2014","unstructured":"Iwamoto T, Hirai H, Yamaguchi N et al (2014) Carboplatin-induced severe hypersensitivity reaction: role of IgE-dependent basophil activation and Fc\u03b5RI. Cancer Sci 105:1472\u20131479","journal-title":"Cancer Sci"},{"key":"1091_CR16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaip.2013.06.002","volume":"1","author":"J Caiado","year":"2013","unstructured":"Caiado J, Venemalm L, Pereira-Santos MC et al (2013) Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy. J Allergy Clin Immunol Pract 1:494\u2013500","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1091_CR17","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1447-0756.2012.01917.x","volume":"39","author":"T Arimoto","year":"2013","unstructured":"Arimoto T, Oda K, Nakagawa S et al (2013) Retreatment with nedaplatin in patients with recurrent gynecological cancer after the development of hypersensitivity reaction to carboplatin. J Obstet Gynaecol Res 39:336\u2013340","journal-title":"J Obstet Gynaecol Res"},{"key":"1091_CR18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1447-0756.2012.01893.x","volume":"39","author":"H Michikami","year":"2013","unstructured":"Michikami H, Minaguchi T, Ochi H et al (2013) Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies. J Obstet Gynaecol Res 39:330\u2013335","journal-title":"J Obstet Gynaecol Res"},{"key":"1091_CR19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-010-1338-5","volume":"67","author":"H Sugimoto","year":"2011","unstructured":"Sugimoto H, Iwamoto T, Murashima Y et al (2011) Risk factors contributing to the development of carboplatin-related delayed hypersensitivity reactions in Japanese patients with gynecologic cancers. Cancer Chemother Pharmacol 67:415\u2013419","journal-title":"Cancer Chemother Pharmacol"},{"key":"1091_CR20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000205263","volume":"76","author":"BH Kim","year":"2009","unstructured":"Kim BH, Bradley T, Tai J et al (2009) Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 76:231\u2013238","journal-title":"Oncology"},{"key":"1091_CR21","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1006\/gyno.2001.6519","volume":"84","author":"DS Dizon","year":"2002","unstructured":"Dizon DS, Sabbatini PJ, Aghajanian C et al (2002) Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 84:378\u2013382","journal-title":"Gynecol Oncol"},{"key":"1091_CR22","first-page":"3465","volume":"23","author":"A Ottaiano","year":"2003","unstructured":"Ottaiano A, Tambaro R, Greggi S et al (2003) Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma. Anticancer Res 23:3465\u20133468","journal-title":"Anticancer Res"},{"key":"1091_CR23","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2009.10.070","volume":"116","author":"R O\u2019Cearbhaill","year":"2010","unstructured":"O\u2019Cearbhaill R, Zhou Q, Iasonos A et al (2010) The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol 116:326\u2013331","journal-title":"Gynecol Oncol"},{"key":"1091_CR24","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/jjco\/hyv081","volume":"45","author":"S Miyamoto","year":"2015","unstructured":"Miyamoto S, Okada R, Ando K (2015) Platinum hypersensitivity and desensitization. Jpn J Clin Oncol 45:795\u2013804","journal-title":"Jpn J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-017-1091-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1091-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-017-1091-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T19:26:32Z","timestamp":1568748392000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-017-1091-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,25]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["1091"],"URL":"https:\/\/doi.org\/10.1007\/s10147-017-1091-4","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,25]]}}}